Seminars in liver disease

Keyphrases

Publications

2024

Manuel Romero-Gómez, Juan Pablo Arab, Claudia P Oliveira, María Hernández, Marco Arrese, Helena Cortez-Pinto, Ramón Bataller
Is There a Safe Alcohol Consumption Limit for the General Population and in Patients with Liver Disease? Seminars in liver disease (2024)
Naoto Fujiwara, Genki Kimura, Hayato Nakagawa
Emerging Roles of Spatial Transcriptomics in Liver Research. Seminars in liver disease (2024)
Naoto Fujiwara, Genki Kimura, Hayato Nakagawa
Emerging role of spatial transcriptomics in liver research. Seminars in liver disease (2024)
J Ma, E S Björnsson, N Chalasani
Hepatotoxicity of Antibiotics and Antifungals and Their Safe Use in Hepatic Impairment. Seminars in liver disease (2024)
Nguyen Pham, Jihane N Benhammou
Statins in chronic liver disease: review of literature and future role. Seminars in liver disease (2024)
Clémence M Canivet, Jérôme Boursier, Rohit Loomba
New Nomenclature for Nonalcoholic Fatty Liver Disease: Understanding Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Dysfunction- and Alcohol-Associated Liver Disease, and Their Implications in Clinical Practice. Seminars in liver disease (2024)
Antonio Saviano, Natascha Roehlen, Thomas F Baumert
Tight Junction Proteins as Therapeutic Targets to Treat Liver Fibrosis and Hepatocellular Carcinoma. Seminars in liver disease (2024)
Takahiro Kodama, Tetsuo Takehara
Molecular genealogy of metabolic-associated hepatocellular carcinoma. Seminars in liver disease (2024)
Steven L Flamm, Alessandra Mangia
Adherence in HCV Treatment: What We Know. Seminars in liver disease (2024)
Takahiro Kodama, Tetsuo Takehara
Molecular Genealogy of Metabolic-associated Hepatocellular Carcinoma. Seminars in liver disease (2024)
Marialena Mouzaki, Jessica G Woo, Senad Divanovic
Gestational and Developmental Contributors of Pediatric MASLD. Seminars in liver disease (2024)
Mohamed El-Kassas, Abeer Awad, Mohamed Elbadry, Juan Pablo Arab
Tailored Model of Care for Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease. Seminars in liver disease (2024)
Oluwashanu Balogun, Kari Nejak-Bowen
Understanding Hepatic Porphyrias: Symptoms, Treatments, and Unmet Needs. Seminars in liver disease (2024)
Anna Tutusaus, Albert Morales, Pablo Garcia de Frutos, Montserrat Mari
GAS6/TAM axis as therapeutic target in liver diseases. Seminars in liver disease (2024)

volume 44, number 1, 2024

Anna Tutusaus, Albert Morales, Pablo García de Frutos, Montserrat Marí
GAS6/TAM Axis as Therapeutic Target in Liver Diseases. Seminars in liver disease 44 (1) (2024)
Fernando Bessone, Geraldine L Hillotte, Natalia Ahumada, Fernanda Jaureguizahar, Anabela C Medeot, Marcelo G Roma
UDCA for Drug-Induced Liver Disease: Clinical and Pathophysiological Basis. Seminars in liver disease 44 (1) (2024)
Katrine Tholstrup Bech, Katrine Prier Lindvig, Maja Sofie Thiele, Laurent Castera
Algorithms for Early Detection of Silent Liver Fibrosis in the Primary Care Setting. Seminars in liver disease 44 (1) (2024)
Hao Liu, Vrishketan Sethi, Xingjie Li, Yao Xiao, Abhinav Humar
Liver Transplantation for Hepatocellular Carcinoma: A Narrative Review and A Glimpse into The Future. Seminars in liver disease 44 (1) (2024)
Hao Liu, Vrishketan Sethi, Xingjie Li, Yao Xiao, Abhinav Humar
Liver Transplantation for Hepatocellular Carcinoma: A Narrative Review and A Glimpse into The Future. Seminars in liver disease 44 (1) (2024)
Manuel Romero-Gómez, Juan Pablo Arab, Claudia P Oliveira, María Hernández, Marco Arrese, Helena Cortez-Pinto, Ramón Bataller
Is There a Safe Alcohol Consumption Limit for the General Population and in Patients with Liver Disease? Seminars in liver disease 44 (1) (2024)
Anna Tutusaus, Albert Morales, Pablo García de Frutos, Montserrat Marí
GAS6/TAM Axis as Therapeutic Target in Liver Diseases. Seminars in liver disease 44 (1) (2024)
Anna Tutusaus, Albert Morales, Pablo García de Frutos, Montserrat Marí
GAS6/TAM Axis as Therapeutic Target in Liver Diseases. Seminars in liver disease 44 (1) (2024)
Clémence M Canivet, Jérôme Boursier, Rohit Loomba
New Nomenclature for Nonalcoholic Fatty Liver Disease: Understanding Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Dysfunction- and Alcohol-Associated Liver Disease, and Their Implications in Clinical Practice. Seminars in liver disease 44 (1) (2024)
Anna Tutusaus, Albert Morales, Pablo García de Frutos, Montserrat Marí
GAS6/TAM Axis as Therapeutic Target in Liver Diseases. Seminars in liver disease 44 (1) (2024)
Manuel Romero-Gómez, Juan Pablo Arab, Claudia P Oliveira, María Hernández, Marco Arrese, Helena Cortez-Pinto, Ramón Bataller
Is There a Safe Alcohol Consumption Limit for the General Population and in Patients with Liver Disease? Seminars in liver disease 44 (1) (2024)
Hao Liu, Vrishketan Sethi, Xingjie Li, Yao Xiao, Abhinav Humar
Corrigendum: Liver Transplantation for Hepatocellular Carcinoma: A Narrative Review and A Glimpse into The Future. Seminars in liver disease 44 (1) (2024)
Anna Tutusaus, Albert Morales, Pablo García de Frutos, Montserrat Marí
GAS6/TAM Axis as Therapeutic Target in Liver Diseases. Seminars in liver disease 44 (1) (2024)
Hao Liu, Vrishketan Sethi, Xingjie Li, Yao Xiao, Abhinav Humar
Liver Transplantation for Hepatocellular Carcinoma: A Narrative Review and A Glimpse into The Future. Seminars in liver disease 44 (1) (2024)
Marialena Mouzaki, Jessica G Woo, Senad Divanovic
Gestational and Developmental Contributors of Pediatric MASLD. Seminars in liver disease 44 (1) (2024)
Clémence M Canivet, Jérôme Boursier, Rohit Loomba
New Nomenclature for Nonalcoholic Fatty Liver Disease: Understanding Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Dysfunction- and Alcohol-Associated Liver Disease, and Their Implications in Clinical Practice. Seminars in liver disease 44 (1) (2024)
Mohamed El-Kassas, Abeer Awad, Mohamed Elbadry, Juan Pablo Arab
Tailored Model of Care for Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease. Seminars in liver disease 44 (1) (2024)
Anna Tutusaus, Albert Morales, Pablo García de Frutos, Montserrat Marí
GAS6/TAM Axis as Therapeutic Target in Liver Diseases. Seminars in liver disease 44 (1) (2024)
Marialena Mouzaki, Jessica G Woo, Senad Divanovic
Gestational and Developmental Contributors of Pediatric MASLD. Seminars in liver disease 44 (1) (2024)
Mohamed El-Kassas, Abeer Awad, Mohamed Elbadry, Juan Pablo Arab
Tailored Model of Care for Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease. Seminars in liver disease 44 (1) (2024)
Fernando Bessone, Geraldine L Hillotte, Natalia Ahumada, Fernanda Jaureguizahar, Anabela C Medeot, Marcelo G Roma
UDCA for Drug-Induced Liver Disease: Clinical and Pathophysiological Basis. Seminars in liver disease 44 (1) (2024)
Hao Liu, Vrishketan Sethi, Xingjie Li, Yao Xiao, Abhinav Humar
Corrigendum: Liver Transplantation for Hepatocellular Carcinoma: A Narrative Review and A Glimpse into The Future. Seminars in liver disease 44 (1) (2024)
Katrine Tholstrup Bech, Katrine Prier Lindvig, Maja Sofie Thiele, Laurent Castera
Algorithms for Early Detection of Silent Liver Fibrosis in the Primary Care Setting. Seminars in liver disease 44 (1) (2024)

volume 44, number 2, 2024

Oluwashanu Balogun, Kari Nejak-Bowen
Understanding Hepatic Porphyrias: Symptoms, Treatments, and Unmet Needs. Seminars in liver disease 44 (2) (2024)
Wiebke Werner, Maria Kuzminskaya, Isabella Lurje, Frank Tacke, Linda Hammerich
Overcoming Resistance to Immune Checkpoint Blockade in Liver Cancer with Combination Therapy: Stronger Together? Seminars in liver disease 44 (2) (2024)
Caiyi Cherry Li, Meng Liu, Hsin-Pei Lee, Wenqi Wu, Lichun Ma
Heterogeneity in Liver Cancer Immune Microenvironment: Emerging Single-Cell and Spatial Perspectives. Seminars in liver disease 44 (2) (2024)
J Ma, E S Björnsson, N Chalasani
Hepatotoxicity of Antibiotics and Antifungals and Their Safe Use in Hepatic Impairment. Seminars in liver disease 44 (2) (2024)
Antonio Saviano, Natascha Roehlen, Thomas F Baumert
Tight Junction Proteins as Therapeutic Targets to Treat Liver Fibrosis and Hepatocellular Carcinoma. Seminars in liver disease 44 (2) (2024)
Nguyen Pham, Jihane N Benhammou
Statins in Chronic Liver Disease: Review of the Literature and Future Role. Seminars in liver disease 44 (2) (2024)
Oluwashanu Balogun, Kari Nejak-Bowen
Understanding Hepatic Porphyrias: Symptoms, Treatments, and Unmet Needs. Seminars in liver disease 44 (2) (2024)
Takahiro Kodama, Tetsuo Takehara
Molecular Genealogy of Metabolic-associated Hepatocellular Carcinoma. Seminars in liver disease 44 (2) (2024)
Steven L Flamm, Alessandra Mangia
Adherence in Hepatitis C Virus Treatment: What We Know. Seminars in liver disease 44 (2) (2024)
Anja M Fischer, Nazim Lechea, Harvey O Coxson
This Is What Metabolic Dysfunction-Associated Steatotic Liver Disease Looks Like: Potential of a Multiparametric MRI Protocol. Seminars in liver disease 44 (2) (2024)
Takahiro Kodama, Tetsuo Takehara
Molecular Genealogy of Metabolic-associated Hepatocellular Carcinoma. Seminars in liver disease 44 (2) (2024)
Wiebke Werner, Maria Kuzminskaya, Isabella Lurje, Frank Tacke, Linda Hammerich
Overcoming Resistance to Immune Checkpoint Blockade in Liver Cancer with Combination Therapy: Stronger Together? Seminars in liver disease 44 (2) (2024)
Naoto Fujiwara, Genki Kimura, Hayato Nakagawa
Emerging Roles of Spatial Transcriptomics in Liver Research. Seminars in liver disease 44 (2) (2024)